CMMB shows severe financial deterioration with R&D expenses surging 168% to $17M while cash burn accelerated dramatically and stockholders' equity declined 41%.
The company is burning through cash at an unsustainable rate with operating cash flow worsening to -$20.4M, while total assets have shrunk by a third in just one year. The massive increase in R&D spending suggests aggressive clinical trial expansion, but with declining cash reserves and deteriorating financial position, the company faces potential funding challenges that could impact its ability to complete ongoing studies.
CMMB experienced severe financial deterioration across all key metrics, with R&D expenses exploding 168% to $17M driving net losses to -$27.6M and operating cash burn to -$20.4M. The balance sheet contracted significantly with total assets falling 33% to $43.1M, stockholders' equity declining 41% to $36.2M, and current liabilities more than doubling to $6.7M. This financial profile indicates an unsustainable cash burn rate that threatens the company's ability to fund operations without additional capital raises, despite the apparent clinical progress suggested by increased R&D spending.
R&D investment increased 168% — signals commitment to future product development, though near-term margin impact.
Current liabilities surged 154.7% — significant near-term obligations; verify ability to meet short-term debt.
Liabilities grew 136.9% — significant increase in debt or obligations, assess impact on financial flexibility.
Net income declined 121.6% — review whether driven by operations, interest costs, or non-recurring items.
Capex reduced 71.5% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Operating cash flow fell 64.6% — earnings quality concerns; investigate working capital changes and non-cash items.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Current assets declined 33.4% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 33.1% — asset sales, write-downs, or balance sheet optimization underway.
Cash decreased 11% — monitor burn rate and upcoming capital needs.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →